Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Description

The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.

Conditions

Brain Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

Condition
Brain Disease
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Stanford University, Palo Alto, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Whole body radiation dose within the last year of less than 5000 mrem
  • 2. Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved
  • 3. Subjects will be at least 21 years of age
  • 4. Subject provides written informed consent
  • 5. Subject is deemed healthy by the PI by via self-reported questionnaire
  • 1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents
  • 2. Participant has a history of or current diagnosis of cancer
  • 3. Participant is pregnant or nursing
  • 4. Metallic implants (contraindicated for MRI)

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Stanford University,

Study Record Dates

2028-03-31